RPG Life Sciences Limited has delivered a strong finish to FY26, reporting robust growth across key businesses, sharp margin performance, and a hefty dividend payout for shareholders.
The pharmaceutical company posted a 23.6% year-on-year jump in revenue from operations in Q4 FY26, rising to Rs. 176.9 crore from Rs. 143.1 crore a year earlier, while maintaining a strong EBITDA margin of 25.6%. For the full year, revenue rose 8.3% to Rs. 707.5 crore, compared with Rs. 653.4 crore in FY25, with FY26 EBITDA margin at 24.4%.
The standout driver was the Domestic Formulations (DF) business, which continued to outperform the market. DF grew 18.2% in Q4, nearly 1.8 times the Indian Pharma Market (IPM) growth of 10.1%, strengthening RPG Life Sciences’ position as the 4th fastest-growing pharma company in India. For the full year, DF grew 13.7% versus IPM’s 8.6%, powered by strong performance in nephrology, oncology, and pain management portfolios.
The API business staged a dramatic recovery, surging 144.3% in Q4, supported by the restart of operations following the fire at its manufacturing facility in January 2025.
Commenting on performance, Managing Director Ashok Nair said: “Overall, we have built solid momentum with healthy growth in Q4 and for the full fiscal year, driven by sharper field effectiveness, operational discipline and an unwavering focus on our key brands.
"The resilience demonstrated by our API business during the year reflects the strength of our teams and the robustness of our operations.
"Looking ahead, we intend to strengthen our new product pipeline, sharpen equity of our existing brands, and drive field force effectiveness. We are also working towards widening our global footprint across fast-growing markets.”
In a shareholder reward move, the Board has recommended a final dividend of Rs. 24 per equity share (300% on face value of Rs. 8) for FY25-26, subject to shareholder approval.
